Post-earnings recap
Reported
Wed, Nov 7, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Nektar Therapeutics reported a narrower-than-expected loss per share, which led to a positive stock reaction, rising 5.18%. The lack of revenue details and guidance suggests uncertainty in financial projections. Investors may be encouraged by the management's focus on clinical trial progress, which could impact future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.56 | N/A | +0.17% |
| Revenue | N/A | N/A | N/A |
Management conveyed a sense of cautious optimism regarding their clinical developments. They emphasized the importance of their ongoing projects.
Management highlighted ongoing progress in clinical trials.
They expressed confidence in their pipeline despite the lack of revenue guidance.